Folkert H. M. Morsink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Folkert H. M. Morsink has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
G. Johan A. Offerhaus
16 shared publications- Christoph Geisenberger
Institute of Pathology Ludwig‐Maximilians‐Universität München Munich Germany
13 shared publications - Gerlof Dirk Valk
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands
13 shared publications - Koen M. A. Dreijerink
Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism 3
13 shared publications - Lodewijk Adriaan Anton Brosens
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
13 shared publications Menno R. Vriens
13 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
NEN-ID local and external cohort scores
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
NEN-ID local and external cohort scores
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Cohort class score descriptives
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Cohort class score descriptives
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Purpose:The primary origin of neuroendocrine tumor metastases can be difficult to determine by histopathology alone, but is critical for therapeutic decision making. DNA methylation–based profiling is now routinely used in the diagnostic workup of brain tumors. This has been enabled by the availability of cost-efficient array-based platforms. We have extended these efforts to augment histopathologic diagnosis in neuroendocrine tumors.Experimental Design:Methylation data was compiled for 69 small intestinal, pulmonary, and pancreatic neuroendocrine tumors. These data were used to build a ridge regression calibrated random forest classification algorithm (neuroendocrine neoplasm identifier, NEN-ID). The model was validated during 3 × 3 nested cross-validation and tested in a local and an external cohort (n = 198 cases).Results:NEN-ID predicted the origin of tumor samples with high accuracy (>95%). In addition, the diagnostic approach was determined to be robust across a range of possible confounding experimental parameters, such as tumor purity and array quality. A software infrastructure and online user interface were built to make the model available to the scientific community.Conclusions:This DNA methylation–based prediction model can be used in the workup for patients with neuroendocrine tumors of unknown primary. To facilitate validation and clinical implementation, we provide a user-friendly, publicly available web-based version of NEN-ID.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Purpose:The primary origin of neuroendocrine tumor metastases can be difficult to determine by histopathology alone, but is critical for therapeutic decision making. DNA methylation–based profiling is now routinely used in the diagnostic workup of brain tumors. This has been enabled by the availability of cost-efficient array-based platforms. We have extended these efforts to augment histopathologic diagnosis in neuroendocrine tumors.Experimental Design:Methylation data was compiled for 69 small intestinal, pulmonary, and pancreatic neuroendocrine tumors. These data were used to build a ridge regression calibrated random forest classification algorithm (neuroendocrine neoplasm identifier, NEN-ID). The model was validated during 3 × 3 nested cross-validation and tested in a local and an external cohort (n = 198 cases).Results:NEN-ID predicted the origin of tumor samples with high accuracy (>95%). In addition, the diagnostic approach was determined to be robust across a range of possible confounding experimental parameters, such as tumor purity and array quality. A software infrastructure and online user interface were built to make the model available to the scientific community.Conclusions:This DNA methylation–based prediction model can be used in the workup for patients with neuroendocrine tumors of unknown primary. To facilitate validation and clinical implementation, we provide a user-friendly, publicly available web-based version of NEN-ID.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Cohort class score descriptives
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Cohort class score descriptives